TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Brokerages

Key Points

• Analyst consensus is “Hold”: Six brokerages cover TScan Therapeutics, with three buy ratings, two holds and one sell; the average 12-month price target is $6.00.
• Shares remain under pressure: TCRX opened at $0.77, near its 52-week low of $0.72 and well below its 52-week high of $2.57. The company has a market capitalization of approximately $50.5 million.
• Quarterly results were mixed: TScan reported an adjusted loss of $0.23 per share, beating estimates for a $0.25 loss, but revenue of $1.05 million fell short of the $1.88 million consensus forecast. Institutional investors own 82.83% of the stock.

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have earned an average rating of "Hold" from the six research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $6.00.

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating on shares of TScan Therapeutics in a research note on Wednesday. Wedbush reissued an "outperform" rating and set a $5.00 target price on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of TScan Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered shares of TScan Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 9th. Finally, Needham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $0.77 on Thursday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.65 and a current ratio of 6.65. The stock has a market capitalization of $50.52 million, a P/E ratio of -0.81 and a beta of 1.06. The company has a 50 day moving average price of $0.91 and a 200 day moving average price of $1.02. TScan Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $2.57.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.88 million. TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%. Equities research analysts forecast that TScan Therapeutics will post -1.11 EPS for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of TScan Therapeutics by 7.8% during the third quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company's stock worth $4,219,000 after acquiring an additional 168,540 shares during the period. Renaissance Technologies LLC boosted its holdings in TScan Therapeutics by 19.6% in the first quarter. Renaissance Technologies LLC now owns 1,364,783 shares of the company's stock valued at $1,378,000 after purchasing an additional 223,714 shares during the period. BlackRock Inc. acquired a new position in TScan Therapeutics during the 2nd quarter worth $975,000. GSA Capital Partners LLP acquired a new position in TScan Therapeutics during the 2nd quarter worth $537,000. Finally, Two Sigma Investments LP increased its holdings in TScan Therapeutics by 14.9% during the 3rd quarter. Two Sigma Investments LP now owns 419,404 shares of the company's stock worth $763,000 after purchasing an additional 54,370 shares during the period. Institutional investors and hedge funds own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan's approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company's pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source